• Nicolas Destefanis, Lorenzo Richiardi. Technical report "Tumore della prostata metastatico in Regione Piemonte", 20.11.2023

• Nicolas Destefanis, Valentina Fiano, Lorenzo Milani, Paolo Vasapolli, Michelangelo Fiorentino, Francesca Giunchi, Luca Lianas, Mauro Del Rio, Francesca Frexia, Luca Pireddu, Luca Molinaro, Paola Cassoni, Mauro Giulio Papotti, Paolo Gontero, Giorgio Calleris, Marco Oderda, Umberto Ricardi, Giuseppe Carlo Iorio, Piero Fariselli, Elena Isaevska, Olof Akre, Renata Zelic, Andreas Pettersson, Daniela Zugna, Lorenzo Richiardi. Cohort profile: the Turin prostate cancer prognostication (TPCP) cohort. Frontiers in Oncology, vol. 13, 2023
  doi: 10.3389/fonc.2023.1242639

• Nicolas Destefanis, Un approccio integrato per il miglioramento della prognosi del tumore alla prostata: obiettivi, metodi e primi risultati della coorte TPCP, XLVII Convegno Associazione Italiana di Epidemiologia, 19.04.2023

Pubblicazioni di riferimento per la coorte TPCP prodotte dal gruppo di lavoro dello studio Turin Prostate Cancer Prognostication. 

• Zelic R, Giunchi F, Fridfeldt J, et al. Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. Clin Epidemiol 2022 Jan 18;14:59-70. doi: 10.2147/CLEP.S339140. eCollection 2022

• Zelic R, Giunchi F, Lianas L, et al. Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer. Sci Rep 2021; 11: 3257. PMID: 33547336

• Zelic R, Garmo H, Zugna D, et al. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. Eur Urol 2020; 77: 180–188. doi:10.1016/j.eururo.2019.09.027. PMID: 31606332 (IF 17.947)

• Zelic R, Zugna D, Bottai M, et al. Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study. Am J Epidemiol 2019;188:1165-1173

• Fiano V, Zugna D, Grasso C, et al. DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer. Clin Epigenetics. 2019;11:152

• Carlsson J, Davidsson S, Fridfeldt J, et al. Quantity and quality of nucleic acids extracted from archival formalin fixed paraffin embedded prostate biopsies. BMC Med Res Methodol 2018;18:161

• Zelic R, Fiano V, Ebot EM, et al. Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality. Prostate Cancer Prostatic Dis. 2018

• Fiano V, Zugna D, Grasso C, et al. LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality. Epigenetics 2017; 12: 11-18

• Zelic R, Fiano V, Zugna D, et al. Global Hypomethylation (LINE-1) and Gene-Specific Hypermethylation (GSTP1) on Initial Negative Prostate Biopsy as Markers of Prostate Cancer on a Rebiopsy. Clin Cancer Res 2016; 15 ;22: 984-92

• Grasso C, Trevisan M, Fiano V, et al. Performance of Different Analytical Software Packages in Quantification of DNA Methylation by Pyrosequencing. PLoS One 2016; 11: e0150483

• Zelic R, Fiano V, Grasso C, et al. Global DNA hypomethylation in prostate cancer development and progression: a systematic review. Prostate Cancer Prostatic Dis 2015;18:1-12